Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era'': Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019)
![Thumbnail](/bitstream/handle/internal/4000/Survival%20with%20Newly%20Diagnosed%20Metastatic%20Prostate%20Cancer%20in%20the%20%e2%80%9cDocetaxel%20Era%e2%80%9d.pdf.jpg?sequence=25&isAllowed=y)
View/ Open
Date
2015-06-01Author
James, ND
Spears, MR
Clarke, NW
Dearnaley, DP
De Bono, JS
Gale, J
Hetherington, J
Hoskin, PJ
Jones, RJ
Laing, R
Lester, JF
McLaren, D
Parker, CC
Parmar, MKB
Ritchie, AWS
Russell, JM
Strebel, RT
Thalmann, GN
Mason, MD
Sydes, MR
Type
Journal Article
Metadata
Show full item recordSubject
Prostate cancer
Natural history
Survival
Time to progression
Control arm cohort
Hormone-naive
Metastatic
Prognostic factors
Prospective data
Research team
Prostate Cancer Targeted Therapy Group
Clinical Academic Radiotherapy (Dearnaley)
Prostate and Bladder Cancer Research
Language
eng
License start date
2015-06
Citation
EUROPEAN UROLOGY, 2015, 67 (6), pp. 1028 - 1038
Publisher
Elsevier BV